TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24809483

Group type: EXPERIMENTAL
Intervention: Part-task training
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Whole-task training
Number of subjects: 23

Group type: COMPARATOR
Intervention: Novice groups (Part-task and Whole-task)
Number of subjects: 23
Study: 23463394

Group type: EXPERIMENTAL
Intervention: Lipiodol
Number of subjects: 103

Group type: COMPARATOR
Intervention: Control
Number of subjects: 103
Study: 22292366

Group type: EXPERIMENTAL
Intervention: Dengzhan group (fleabane injection and Dengzhan Shengmai capsules)
Number of subjects: 678

Group type: COMPARATOR
Intervention: Western medicine group (WM group)
Number of subjects: 678
Study: 19116750

Group type: EXPERIMENTAL
Intervention: Laparoscopic group (LG)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Open group (OG)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 84
Study: 16464386

Group type: EXPERIMENTAL
Intervention: Urinastatin treatment (300 kU for severe burns, 200 kU for moderate burns) administered intravenously twice a day for 5 to 7 days
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group received routine therapy
Number of subjects: 72
Study: 15471303

Group type: EXPERIMENTAL
Intervention: Vaccine group (influenza vaccine composed of A/Texas/36/91 (H1N1), A/Nanchang/933/95 (H3N2), and B/Harbin/07/94 strains)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Vaccine group
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Patients without protective HI antibody to A (H1N1)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Patients without protective HI antibody to A (H3N2)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Patients without protective HI antibody to B
Number of subjects: 123
Study: 10692805

Group type: EXPERIMENTAL
Intervention: Muscle relaxation training
Number of subjects: 0
Study: 9349062

Group type: EXPERIMENTAL
Intervention: Cisatracurium 0.1 mg.kg‐1 followed by infusion of 3 micrograms.kg‐1.min‐1
Number of subjects: 20

Group type: COMPARATOR
Intervention: Atracurium 0.5 mg.kg‐1 followed by infusion of 10 micrograms.kg‐1.min‐1
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Cisatracurium
Number of subjects: 20

Group type: COMPARATOR
Intervention: Atracurium
Number of subjects: 20
Study: 7692617

Group type: EXPERIMENTAL
Intervention: Mepacrine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Bleomycin
Number of subjects: 40
Study: 3159552

Group type: EXPERIMENTAL
Intervention: 6.25 percent aluminum chloride in anhydrous alcohol
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo (alcohol alone)
Number of subjects: 25
Study: 30236136

Group type: EXPERIMENTAL
Intervention: LigaSure Small Jaw (LSJ)
Number of subjects: 550

Group type: COMPARATOR
Intervention: Conventional technique
Number of subjects: 550
Study: 27156182

Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri DSM 17938
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study: 24730528

Group type: EXPERIMENTAL
Intervention: SMS intervention
Number of subjects: 80

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 80
Study: 21540760

Group type: COMPARATOR
Intervention: 10-valent pneumococcal nontypeable Haemophilus influenzae Protein D Conjugate Vaccine (PHiD-CV)
Number of subjects: 600
Study: 20042092

Group type: EXPERIMENTAL
Intervention: High fiber diet (instruction to achieve daily dietary fiber intake of 30 g or more)
Number of subjects: 240

Group type: COMPARATOR
Intervention: American Heart Association (AHA) diet (instruction to make several dietary changes recommended by AHA 2006 guidelines)
Number of subjects: 240
Study: 17459333

Group type: EXPERIMENTAL
Intervention: High-perceived responsibility condition
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Repeated checking task
Number of subjects: 15

Group type: COMPARATOR
Intervention: Student control sample
Number of subjects: 15
Study: 16036076

Group type: EXPERIMENTAL
Intervention: Teriparatide (rhPTH [1‐34])
Number of subjects: 0

Group type: COMPARATOR
Intervention: Combination of PTH with other agents (estrogens, calcitonin, bisphosphonates)
Number of subjects: 0
Study: 11451272

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIg) therapy for 26 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIg) therapy
Number of subjects: 20
Study: 9331351

Group type: EXPERIMENTAL
Intervention: Cocaine (0.6 mg/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 0
Study: 7530680

Group type: EXPERIMENTAL
Intervention: Unilateral salpingo-oophorectomy with preservation of the contralateral ovary and uterus
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Postoperative chemotherapy with bleomycin, etoposide, and cisplatin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chemotherapy for metastatic dysgerminoma
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Surgery alone for OSCST
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Platinum-based combination chemotherapy for OSCST with poor differentiation
Number of subjects: 0
Study: 2980866

Group type: EXPERIMENTAL
Intervention: naloxone (10 mg sc)
Number of subjects: 10

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 10
Study: 224345

Group type: EXPERIMENTAL
Intervention: Arsenic exposure in copper‐smelting factory workers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Subclinical neuropathy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clinical neuropathy
Number of subjects: 0
Study: 31116140

Group type: EXPERIMENTAL
Intervention: Palliative gastrectomy
Number of subjects: 0
Study: 27797402

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Number of subjects: 85
Study: 25875011

Group type: EXPERIMENTAL
Intervention: Visceral osteopathic treatment (3 times during the first week of life)
Number of subjects: 41

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Visceral osteopathic treatment
Number of subjects: 41
Study: 23813263

Group type: EXPERIMENTAL
Intervention: FL/milk
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: FL/juice
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: FL/water
Number of subjects: 20

Group type: COMPARATOR
Intervention: FL
Number of subjects: 20
Study: 21407247

Group type: EXPERIMENTAL
Intervention: Walnut-enriched meat
Number of subjects: 22

Group type: COMPARATOR
Intervention: Low-fat meat (LM)
Number of subjects: 22
Study: 19366151

Group type: EXPERIMENTAL
Intervention: Auto-iliac bone transplantation (group A)
Number of subjects: 72

Group type: COMPARATOR
Intervention: MSCs transplantation derived from human umbilical cord (group B)
Number of subjects: 72
Study: 17925087

Group type: COMPARATOR
Intervention: Visual Inspection with Acetic Acid (VIA)
Number of subjects: 56147

Group type: COMPARATOR
Intervention: Visual Inspection with Lugol's Iodine (VILI)
Number of subjects: 56147

Group type: EXPERIMENTAL
Intervention: Combined test (VIA + VILI)
Number of subjects: 56147

Group type: COMPARATOR
Intervention: Combined test vs VIA alone
Number of subjects: 56147

Group type: COMPARATOR
Intervention: Combined test vs VILI alone
Number of subjects: 56147

Group type: EXPERIMENTAL
Intervention: Combined test
Number of subjects: 56147

Group type: COMPARATOR
Intervention: VILI as single test
Number of subjects: 56147
Study: 14534771

Group type: COMPARATOR
Intervention: Nicotine patches (Nicotrol) 5 mg/day during week 1, 10 mg/day during week 2 and week 3, 5 mg/day during week 4
Number of subjects: 11

Group type: COMPARATOR
Intervention: Nicotine patches (Nicotrol)
Number of subjects: 11
Study: 11368437

Group type: EXPERIMENTAL
Intervention: MEC (mitoxantrone, etoposide, and cytarabine) plus PSC 833
Number of subjects: 23
Study: 9553686

Group type: EXPERIMENTAL
Intervention: Patch 7D (7-day estradiol transdermal patch)
Number of subjects: 18
Study: 8139084

Group type: EXPERIMENTAL
Intervention: Tacrine
Number of subjects: 2446

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2446
Study: 3048363

Group type: EXPERIMENTAL
Intervention: Supervised directed coughing
Number of subjects: 38

Group type: COMPARATOR
Intervention: Conventional physiotherapy (postural drainage, vibration and/or percussion and coughing)
Number of subjects: 38
Study: 30589600

Group type: COMPARATOR
Intervention: Triptorelin 3.75 mg plus letrozole 2.5 mg/day
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Degarelix 240 mg (day 1 of cycle 1) then 80 mg (day 1 of cycles 2-6) plus letrozole 2.5 mg/day
Number of subjects: 51

Group type: COMPARATOR
Intervention: Triptorelin plus letrozole
Number of subjects: 51
Study: 28322071

Group type: EXPERIMENTAL
Intervention: High-fat meal with normal bolus insulin and an additional 30% insulin bolus administered 3-h post-meal (HFA)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Low-fat meal with normal bolus insulin
Number of subjects: 10

Group type: COMPARATOR
Intervention: High-fat meal with normal bolus insulin
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: All conditions
Number of subjects: 10
Study: 25585612

Group type: EXPERIMENTAL
Intervention: One anastomosis gastric bypass (OAGB)
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Control group (Roux-en-Y gastric bypass - RYGB)
Number of subjects: 1000
Study: 23043683

Group type: EXPERIMENTAL
Intervention: Cholecalciferol (vitamin D3) 2000 IU/day for 6 months
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo for 6 months
Number of subjects: 28
Study: 20825496

Group type: EXPERIMENTAL
Intervention: Donepezil treatment
Number of subjects: 114
Study: 18331283

Group type: EXPERIMENTAL
Intervention: H. perforatum extract (300 mg, hypericin 0.31% and hyperforin 3.0%) taken three times a day for 12 weeks
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo (indistinguishable capsules) taken three times a day for 12 weeks
Number of subjects: 43
Study: 17244684

Group type: EXPERIMENTAL
Intervention: Oral beclomethasone dipropionate (BDP) 8 mg/d for 50 days
Number of subjects: 129

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 129
Study: 14693409

Group type: EXPERIMENTAL
Intervention: Troglitazone 400 mg daily for 12 weeks
Number of subjects: 34

Group type: COMPARATOR
Intervention: Metformin 750 mg daily
Number of subjects: 34
Study: 11699125

Group type: EXPERIMENTAL
Intervention: Protocol A (immediate denudation, immediate injection)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Protocol B (delayed denudation, delayed injection)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Protocol C (early denudation, delayed injection)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Preincubation with intact cumulus
Number of subjects: 141

Group type: COMPARATOR
Intervention: No preincubation (implied control)
Number of subjects: 141
Study: 9460726

Group type: EXPERIMENTAL
Intervention: Word fluency task with random production criteria
Number of subjects: 0

Group type: COMPARATOR
Intervention: Word fluency task
Number of subjects: 0
Study: 7957521

Group type: EXPERIMENTAL
Intervention: Intravenous colchicine 0.5 mg (healthy volunteers)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Intravenous colchicine 1 mg (elderly group)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Intravenous colchicine (both groups)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Intravenous colchicine (healthy volunteers)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Intravenous colchicine (elderly subjects)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Intravenous colchicine (healthy group)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Intravenous colchicine (elderly group)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Oral colchicine 1 mg (healthy volunteers)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Oral colchicine 1 mg (elderly subjects)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Oral colchicine (both groups)
Number of subjects: 10
Study: 2824297

Group type: EXPERIMENTAL
Intervention: Topical human fibroblast interferon (HuIFN‐beta) 7.5 x 10(5) IU/ml, one drop 5 times daily
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 30063152

Group type: EXPERIMENTAL
Intervention: Nitrous Oxide (RA technique)
Number of subjects: 90
Study: 28557747

Group type: EXPERIMENTAL
Intervention: Iodide supplementation (sodium iodide, 30 μg/kg per day)
Number of subjects: 1273

Group type: COMPARATOR
Intervention: Placebo (sodium chloride, 30 μg/kg per day)
Number of subjects: 1273
Study: 26034741

Group type: EXPERIMENTAL
Intervention: Biofeedback therapy
Number of subjects: 22

Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 22
Study: 23824214

Group type: EXPERIMENTAL
Intervention: Dose reduction/discontinuation (DR) strategy
Number of subjects: 128

Group type: COMPARATOR
Intervention: Maintenance treatment (MT)
Number of subjects: 128
Study: 20335543

Group type: EXPERIMENTAL
Intervention: 15 g soy protein and 100 mg isoflavones
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: 15 g milk protein and 100 mg isoflavones
Number of subjects: 180

Group type: COMPARATOR
Intervention: 15 g milk protein
Number of subjects: 180
Study: 18068888

Group type: EXPERIMENTAL
Intervention: Moving ambulance vehicle
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Flying helicopter
Number of subjects: 11

Group type: COMPARATOR
Intervention: Staying at the scene (control)
Number of subjects: 11
Study: 17075740

Group type: EXPERIMENTAL
Intervention: Workshop to teach prioritization of preventive services
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 14693167

Group type: EXPERIMENTAL
Intervention: Patients with PAD
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Patients with ischaemic rest pain
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Patients with ABPI < 0.52
Number of subjects: 234

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 234
Study: 11094589

Group type: EXPERIMENTAL
Intervention: Vecuronium administered after 15 min of sevoflurane exposure
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Vecuronium administered after 30 min of sevoflurane exposure
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Vecuronium administered after 60 min of sevoflurane exposure
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Vecuronium administered after 90 min of sevoflurane exposure
Number of subjects: 40
Study: 8838440

Group type: COMPARATOR
Intervention: Meloxicam 5 mg
Number of subjects: 44

Group type: COMPARATOR
Intervention: Meloxicam 10 mg
Number of subjects: 44

Group type: COMPARATOR
Intervention: Meloxicam 20 mg
Number of subjects: 44

Group type: COMPARATOR
Intervention: Meloxicam 30 mg
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Meloxicam 15 mg (i.v.)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Meloxicam 15 mg (i.m.)
Number of subjects: 44
Study: 1562335

Group type: EXPERIMENTAL
Intervention: Enlarging intravenous (IV) catheter
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard Teflon IV catheters
Number of subjects: 30
Study: 3907425

Group type: EXPERIMENTAL
Intervention: Ketotifen (1 mg b.i.d.)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 30607809

Group type: EXPERIMENTAL
Intervention: EQ-5D-3L
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: EQ-5D-5L
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: SF-6D
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: HUI3
Number of subjects: 148
Study: 29351736

Group type: EXPERIMENTAL
Intervention: Audiovisual introduction
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Camera focus on patient at emotional moments
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Physician-only variant with audiovisual introduction
Number of subjects: 181

Group type: COMPARATOR
Intervention: Written introduction
Number of subjects: 181

Group type: COMPARATOR
Intervention: Camera focus on physician only and neutral moments
Number of subjects: 181

Group type: COMPARATOR
Intervention: Camera focus on physician and patient at neutral moments
Number of subjects: 181
Study: 27513477

Group type: EXPERIMENTAL
Intervention: Brief psychological intervention based on gratitude and mindfulness for 4 weeks
Number of subjects: 120

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 120
Study: 24126899

Group type: EXPERIMENTAL
Intervention: Closed basket weave (CBW) ankle taping
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 12
Study: 22487150

Group type: EXPERIMENTAL
Intervention: Cycling exercise at 30% of maximal oxygen consumption (%VO(2max)) for 60 min
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Cycling exercise at 50% of maximal oxygen consumption (%VO(2max)) for 30 min
Number of subjects: 7
Study: 20473046

Group type: EXPERIMENTAL
Intervention: Acceptance Commitment Therapy self-help book with weekly telephone support
Number of subjects: 11

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 11
Study: 17986525

Group type: EXPERIMENTAL
Intervention: Vildagliptin 100 mg with Amlodipine 5 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vildagliptin 100 mg with Valsartan 320 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vildagliptin 100 mg with Ramipril 5 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vildagliptin alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vildagliptin with Amlodipine, Valsartan, or Ramipril
Number of subjects: 0
Study: 16208642

Group type: EXPERIMENTAL
Intervention: Virtual Rheumatology CD
Number of subjects: 354

Group type: COMPARATOR
Intervention: Non-CD group
Number of subjects: 354
Study: 11811571

Group type: EXPERIMENTAL
Intervention: Creatine (2 g) in solution
Number of subjects: 5

Group type: COMPARATOR
Intervention: Creatine in meat
Number of subjects: 5

Group type: COMPARATOR
Intervention: Creatine as a lozenge (solid form)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Creatine as a crystalline suspension in ice cold water
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Creatine in solution (as a control)
Number of subjects: 5
Study: 10524687

Group type: EXPERIMENTAL
Intervention: Prosorba column treatment
Number of subjects: 91

Group type: COMPARATOR
Intervention: Sham apheresis
Number of subjects: 91
Study: 8523876

Group type: EXPERIMENTAL
Intervention: Methylprednisolone before cardiopulmonary bypass
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Low-dose aprotinin protocol
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 24
Study: 1724023

Group type: EXPERIMENTAL
Intervention: Intrapulmonary and endobronchial administration of antibiotics and contrykal
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Intravenous droplet contrykal
Number of subjects: 89

Group type: COMPARATOR
Intervention: Conventional treatment with antibacterial and antiproteolytic drugs
Number of subjects: 89
Study: 7048914

Group type: EXPERIMENTAL
Intervention: Intravenous acyclovir
Number of subjects: 97

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97
Study: 30797258

Group type: EXPERIMENTAL
Intervention: Colgate TotalSF containing 0.454% SnF2 and 1% zinc phosphate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Regular fluoride toothpaste
Number of subjects: 0
Study: 29723896

Group type: EXPERIMENTAL
Intervention: Eplerenone 25 mg once daily (up-titrated to 50 mg/day after 4 weeks)
Number of subjects: 110

Group type: COMPARATOR
Intervention: MR blocker treatment
Number of subjects: 110
Study: 26878894

Group type: EXPERIMENTAL
Intervention: Personalized normalized feedback on gambling status by email
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Self-help book with a Cognitive Behavioral Therapy (CBT) program without guidance
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CBT program emailed weekly by a trained psychologist with personalized guidance
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waiting list (control group)
Number of subjects: 0
Study: 24551191

Group type: EXPERIMENTAL
Intervention: Parental perception of child's weight status
Number of subjects: 783

Group type: EXPERIMENTAL
Intervention: Parental misperception
Number of subjects: 783

Group type: EXPERIMENTAL
Intervention: Parental intention to improve child overweight-related health behavior
Number of subjects: 783

Group type: EXPERIMENTAL
Intervention: Child meeting guidelines of health behaviors
Number of subjects: 783
Study: 22762376

Group type: EXPERIMENTAL
Intervention: FitFor2 exercise program (aerobic and strengthening exercises, two sessions per week)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: FitFor2 exercise program
Number of subjects: 121
Study: 21072898

Group type: EXPERIMENTAL
Intervention: PPI (lansoprazole 30 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: H2RA (famotidine 40 mg or ranitidine 300 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Both groups (PPI and H2RA)
Number of subjects: 60
Study: 17999221

Group type: EXPERIMENTAL
Intervention: Higher levels of anxiety
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cognitive anxiety
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Individual difference variables
Number of subjects: 0
Study: 15023168

Group type: EXPERIMENTAL
Intervention: Proton pump inhibitor treatment with surgery (group 1)
Number of subjects: 228

Group type: COMPARATOR
Intervention: Proton pump inhibitor treatment without surgery (group 2)
Number of subjects: 228
Study: 12116723

Group type: EXPERIMENTAL
Intervention: Powered toothbrush
Number of subjects: 80

Group type: COMPARATOR
Intervention: Manual toothbrush
Number of subjects: 80
Study: 10439688

Group type: EXPERIMENTAL
Intervention: Intensive treatment (n = 80)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Standard treatment (n = 80)
Number of subjects: 160
Study: 7843710

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study: 2240641

Group type: EXPERIMENTAL
Intervention: 0.5% lidocaine with epinephrine
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 1.0% lidocaine with epinephrine
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 1.5% lidocaine with epinephrine
Number of subjects: 45

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 45
Study: 595585

Group type: EXPERIMENTAL
Intervention: Human chorionic gonadotropin (HCG) injections
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo injections
Number of subjects: 0
Study: 31329489

Group type: EXPERIMENTAL
Intervention: Alirocumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0